Ankylosing Spondylitis Market Statistics 2030:
The global ankylosing spondylitis market size was valued at $5,140.94 million in 2020, and is projected to reach $8,110.59 million by 2030, registering a CAGR of 4.6% from 2021 to 2030. The ankylosing spondylitis is an inflammatory disease that can cause some of the bones in the spine (vertebrae) to fuse over time. This fusing makes the spine less flexible and can result in a hunched posture. If ribs are affected, it can be difficult to breathe deeply. Ankylosing spondylitis is a complex disorder that can cause some serious complications when left unchecked.
Symptoms and complications for many patients can be controlled or reduced by following a regular treatment plan. The early signs and symptoms of ankylosing spondylitis might include pain and stiffness in the lower back and hips, especially in the morning and after periods of inactivity. Neck pain and fatigue also are common. Over time, symptoms might worsen, improve or stop at irregular intervals.
The ankylosing spondylitis has no known specific cause, though genetic factors seem to be involved. In particular, people who have a gene called HLA-B27 are at a greatly increased risk of developing ankylosing spondylitis. However, only some people with the gene develop the condition. The ankylosing spondylitis can be diagnosed with physical examination. In addition, MRI and X-ray imaging tests are performed for diagnosis of ankylosing spondylitis.
The ankylosing spondylitis cannot be cured or treated completely but symptoms of disease can be managed with drug treatment and physical exercise. For the management of pain associated with ankylosing spondylitis generally NSAIDs are preferred. In addition, TNF inhibitors, corticosteroids and disease-modifying antirheumatic drugs (DMARDs) are used for management of inflammation in ankylosing spondylitis. Furthermore, monoclonal antibodies has been approved for treatment of ankylosing spondylitis.
The growth of the global ankylosing spondylitis market is majorly driven by an increase in prevalence of ankylosing spondylitis. For instance, according to paper published in Scandinavian Journal of Rheumatology, in 2020, titled ‘Prevalence of ankylosing spondylitis in Spain’, the study found that about 7.3% population shows positive screening for ankylosing spondylitis. Furthermore, rise in number of orthopedic hospitals and diagnostic centers boost the diagnosis and treatment of diseases. For instance, according to Definitive Healthcare data in 2020 there are more than 30,500 orthopedic surgeons in the U.S.
Moreover, advancement in ankylosing spondylitis therapy is anticipated to contribute toward the growth of the ankylosing spondylitis market. For instance, in August, 2019, Lilly, a leading manufacturer of biopharmaceuticals, receives U.S. FDA Approval for Taltz (ixekizumab) for the Treatment of Active Ankylosing Spondylitis. Taltz is a monoclonal antibody used to reduce inflammation and pain. However, high cost of ankylosing spondylitis therapy and adverse effects of drugs used for treatment of ankylosing spondylitis restricted the market growth during the forecast period.
Global Ankylosing Spondylitis Market Segmentation
The ankylosing spondylitis market is segmented on the basis of drug class, distribution channel, and region. By drug class, the market is mainly categorized into NSAIDs, TNF inhibitors and others.
Depending on distribution channel, it is categorized hospitals pharmacy, retail pharmacy, and online pharmacy.
Region-wise, the ankylosing spondylitis market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Arabia, South Africa, and LAMEA).
By Drug Class
NSAIDs segment held a dominant position in 2020 and would continue to maintain the lead over the forecast period.
Segment Review
Depending on drug class, the NSAIDs segment dominated the ankylosing spondylitis market in 2020, and this trend is expected to continue during the forecast period, owing to increase in ankylosing spondylitis. However, the TNF inhibitors segment is expected to witness considerable growth during the forecast period, owing to rise in advancements in ankylosing spondylitis therapy.
Depending on distribution channel, the retail pharmacy segment was the major contributor in 2020 and is expected to maintain its lead during the forecast period, owing to an increase in number of retail pharmacies and easy to reach for patients. However, the hospital pharmacy segment is expected to witness considerable growth during the forecast period, due to rise in number of hospitals.
By Distribution Channel
Retail Pharmacy segment held a dominant position in 2020 and would continue to maintain the lead over the forecast period.
North America garnered the major share in the ankylosing spondylitis market in 2020, and is expected to continue to dominate during the forecast period, owing to rise in prevalence of ankylosing spondylitis, presence of key players for manufacturing & development of drugs for ankylosing spondylitis treatment, and well-established infrastructure in the region. However, Asia-Pacific is expected to register the highest CAGR of 6.1% from 2021 to 2030, owing to an increase in the number of hospitals, and a high population.
The key players operating in the global ankylosing spondylitis market include AbbVie, Inc, Amgen, Inc, Pfizer, Inc, Novartis AG, Eli Lilly and Company, UCB, Inc., Gilead Sciences, Reliance Life Sciences Pvt. Ltd, Janssen Pharmaceuticals, and Merck & Co. Inc.
By Region
North America was holding a dominant position in 2020 and would continue to maintain the lead over the analysis period.
Key Benefits For Stakeholders
- The report provides an in-depth analysis of the global ankylosing spondylitis market size along with the current trends and future estimations to elucidate the imminent investment pockets.
- It offers market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the ankylosing spondylitis market.
- A comprehensive analysis of the region assists to understand the regional ankylosing spondylitis market and facilitate strategic business planning and determine prevailing opportunities.
- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global ankylosing spondylitis market growth.
Ankylosing Spondylitis Market Report Highlights
| Aspects | Details |
 By Drug Class |
|
 By Distribution Channel |
|
 By Region |
|
 By Key Market Players |
|
Analyst Review
Ankylosing spondylitis is a type of arthritis that mainly affects the spine and pelvis bone.
The ankylosing spondylitis drug class includes the NSAIDs, TNF inhibitors and others. The NSAIDs used for the management of pain and inflammation. NSAIDs dominates the market owing to advancement in treatment of ankylosing spondylitis.
The factors such as increased in prevalence of ankylosing spondylitis, rise in number of hospitals, and advancements in ankylosing spondylitis advancement & treatment. In addition, initiatives taken by the government to treat and improve lifestyle of patients are expected to drive the growth of the ankylosing spondylitis market.
North America is expected to witness the highest growth, in terms of revenue, owing to rise in prevalence of ankylosing spondylitis, the presence of key players for manufacturing and developing ankylosing spondylitis, and increase in number of hospitals and diagnostic centers, in the region.
However, the high cost of associated with ankylosing spondylitis treatment and lack of healthcare facilities can hamper market growth.
The total market value of Ankylosing spondylitis market is $5140.94 million in 2020.
The forecast period in the report is from 2021 to 2030
The market value of Ankylosing spondylitis market in 2021 was $5390.79 million
The base year for the report is 2020.
Yes, ankylosing spondylitis companies are profiled in the report
The top companies that hold the market share in Ankylosing spondylitis market are AbbVie, Inc, Amgen, Inc, Pfizer, Inc, Novartis AG, Eli Lilly and Company, UCB, Inc., Gilead Sciences, Reliance Life Sciences Pvt. Ltd, Janssen Pharmaceuticals, and Merck & Co. Inc.
Asia-Pacific is expected to register the highest CAGR of 6.10% from 2021 to 2030, owing to increase in number of hospitals, a rise in number of ankylosing spondylitis patients, and high population.
The key trends in the Ankylosing spondylitis market are by an increase in the prevalence of ankylosing spondylitis; and R&D in the ankylosing spondylitis sector.
Loading Table Of Content...
